Peter Greenleaf - 02 Jan 2026 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AUPH
Reported as of: 02 Jan 2026
Net transaction value: -$1,805,046
SEC form: 4
Accepted by SEC: 05 Jan 2026, 16:10:03 UTC
Prior SEC filing: 01 Apr 2026
Next SEC filing: 23 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter S. Greenleaf

Key filing fact

Peter Greenleaf filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 05 Jan 2026.

Key facts

This page summarizes Peter Greenleaf's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 05 Jan 2026, 16:10.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: -$1,805,046.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001363683 Primary reporting owner

Greenleaf Peter

Relationship: Chief Executive Officer, Director
Address: #140, 14315-118 AVENUE, EDMONTON, ALBERTA, CANADA
Signature: /s/ Peter S. Greenleaf
Signature date: 05 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Award

Transaction value: $0
Shares: +165,384
Change %: +9.2%
Price: $0.000000
Shares after: 1,954,329
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1

AUPH transaction

Common Stock

Tax liability

Transaction value: $1,805,046
Shares: -113,169
Change %: -5.8%
Price: $15.95
Shares after: 1,845,037
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents the number of shares earned upon certification of performance for a performance award payable solely in common shares of the Issuer that vest in two (2) equal annual installments on December 31, 2025 and December 31, 2026.

Footnote F2

Represents shares withheld to satisfy tax withholding obligations upon the vesting of performance awards.

Footnote F3

Includes common shares acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,257 common shares were acquired on May 30, 2025 and 1,620 common shares were acquired on November 28, 2025.